SALUTENSIN-DEMI
Clinical safety rating
cautionComprehensive clinical and safety monograph for SALUTENSIN-DEMI (SALUTENSIN-DEMI).
Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.
| Metabolism | Hydroflumethiazide is minimally metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes. |
| Excretion | Renal: hydrochlorothiazide 70% unchanged, reserpine <1% unchanged; fecal: reserpine ~6% as metabolites |
| Half-life | Hydrochlorothiazide: 6-15 hours (terminal), clinical effect lasts 6-12 hours; Reserpine: 50-100 hours (terminal), with prolonged action due to irreversible vesicular depletion |
| Protein binding | Hydrochlorothiazide: 40-68% (primarily to albumin); Reserpine: approximately 40% (to albumin and α1-acid glycoprotein) |
| Volume of Distribution | Hydrochlorothiazide: 0.2-0.4 L/kg (distributes in extracellular fluid); Reserpine: 5-10 L/kg (extensive tissue distribution, high affinity for adrenergic neurons) |
| Bioavailability | Oral: hydrochlorothiazide 65-75%; reserpine 30-50% (extensive first-pass metabolism) |
| Onset of Action | Oral: hydrochlorothiazide diuresis begins within 2 hours, peak in 4-6 hours; reserpine hypotensive effect in 3-6 days (gradual onset) |
| Duration of Action | Hydrochlorothiazide: diuretic effect ~6-12 hours; Reserpine: hypotensive effect persists for 1-6 weeks after discontinuation due to irreversible binding to amine storage vesicles |
| Molecular Weight | 303.35 |
1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in GFR <30 mL/min. For GFR 30-50 mL/min: use maximum 1 tablet daily; monitor electrolytes and renal function. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., every other day). Child-Pugh C: contraindicated due to risk of hepatic encephalopathy. |
| Pediatric use | Not recommended for pediatric use due to lack of safety and efficacy data; alternative agents preferred. |
| Geriatric use | Start with 0.5 tablet (7.5 mg hydrochlorothiazide + 0.0375 mg clonidine) once daily; monitor for orthostatic hypotension, electrolyte imbalance, and renal function; avoid in patients with high frailty. |
| 1st trimester | Avoid unless compelling need; thiazide diuretics may cause fetal harm based on case reports suggesting congenital anomalies. |
| 2nd trimester | Use only if clearly needed; may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. |
| 3rd trimester | Use only if clearly needed; risk of fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. |
Clinical note
Comprehensive clinical and safety monograph for SALUTENSIN-DEMI (SALUTENSIN-DEMI).
| Placental transfer | Thiazide diuretics cross the placenta; degree of transfer is moderate based on animal and human data. |
| Breastfeeding | Thiazide diuretics are excreted in breast milk in low amounts; may suppress lactation and cause neonatal jaundice or electrolyte disturbances. Use with caution, especially in high doses. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Possible risk of congenital malformations based on animal studies; human data limited. Second and third trimesters: Fetal hypotension, renal dysfunction, oligohydramnios, skull ossification delay. Avoid use unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, electrolytes, fetal growth, amniotic fluid volume via ultrasound, and fetal heart rate. |
| Fertility Effects | No specific human data; animal studies show no significant effect on fertility. Potential for reversible alterations in spermatogenesis or ovulation with some antihypertensives. Monitor reproductive function in patients attempting conception. |
■ FDA Black Box Warning
None.
| Serious Effects |
AnuriaHypersensitivity to hydrochlorothiazide or other thiazidesSevere hepatic impairment
| Precautions | Electrolyte imbalances (hypokalemia, hyponatremia), Orthostatic hypotension, Depression (reserpine component), Potential for increased risk of non-melanoma skin cancer with thiazide diuretics, May exacerbate systemic lupus erythematosus |
| Food/Dietary | Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, leafy greens) as thiazide can cause potassium loss; however, reserpine may increase potassium retention. Maintain balanced diet. Limit sodium intake to control blood pressure. Avoid grapefruit juice as it may increase reserpine absorption. |
| Clinical Pearls | Salutensin-demi contains reserpine (rauwolfia alkaloid) and a thiazide diuretic. Monitor for depression, nasal stuffiness, and hypotension. Avoid concurrent MAOIs. Use with caution in patients with a history of peptic ulcer disease due to increased gastric acid secretion from reserpine. |
| Patient Advice | Take exactly as prescribed, usually once daily in the morning. · Avoid sudden discontinuation; taper dose to prevent rebound hypertension. · Report signs of depression, nightmares, or severe drowsiness. · May cause dizziness upon standing; rise slowly from sitting or lying. · Notify your doctor if you develop abdominal pain, black stools, or unusual bleeding. · Avoid alcohol, which can increase drowsiness and hypotension. · Take with food or milk to lessen stomach upset. |
Loading safety data…